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Abstract
Background: We have previously demonstrated protective efficacy against B. melitensis using formulations of
naked DNA vaccines encoding genes ialB and omp25. The present study was undertaken to further understand the
immune response generated by the protective vaccination regimens and to evaluate cationic liposome adsorption
as a delivery method to improve vaccine utility.
Methods: The protective efficacy and immunogenicity of vaccines delivered as four doses of naked DNA, a single
dose of naked DNA or a single dose of DNA surface adsorbed to cationic liposomes were compared using the
BALB/c murine infection model of B. melitensis. Antigen-specific T cells and antibody responses were compared
between the various formulations.
Results: The four dose vaccination strategy was confirmed to be protective against B. melitensis challenge. The
immune response elicited by the various vaccines was found to be dependent upon both the antigen and the
delivery strategy, with the IalB antigen favouring CD4+ T cell priming and Omp25 antigen favouring CD8+.
Delivery of the p-ialB construct as a lipoplex improved antibody generation in comparison to the equivalent
quantity of naked DNA. Delivery of p-omp25 as a lipoplex altered the profile of responsive T cells from CD8+ to
CD4+ dominated. Under these conditions neither candidate delivered by single dose naked DNA or lipoplex
vaccination methods was able to produce a robust protective effect.
Conclusions: Delivery of the p-omp25 and p-ialB DNA vaccine candidates as a lipoplex was able to enhance
antibody production and effect CD4+ T cell priming, but was insufficient to promote protection from a single dose
of either vaccine. The enhancement of immunogenicity by lipoplex delivery is a promising step toward improving
the practicality of these two candidate vaccines, and suggests that this lipoplex formulation may be of value in
situations where improvements to CD4+ responses are required. However, in the case of Brucella vaccine
development it is suggested that further modifications to the candidate vaccines and delivery strategies will be
required in order to deliver sustained protection.
Background
Brucellosis is a worldwide zoonosis of considerable
social and economic importance. In livestock the princi-
pal clinical outcome of brucellosis is abortion. In
humans the disease manifests as a debilitating flu-like
illness which, if left untreated, can persist to become
chronic with a variety of unpleasant sequelae. The dis-
ease is largely considered to be an occupational zoonosis
as natural human infection is acquired through direct
contact with the organism and most usually associated
with contact with infected animals or animal products.
In addition, brucellosis is one of the most frequently
reported laboratory acquired bacterial infections and
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Brucella spp., are also considered potential biothreat
agents (For review [1]). Whilst Great Britain and a large
proportion of the developed world are designated as
Officially Brucella Free (OBF), a considerable number of
countries remain endemic for this debilitating zoonosis.
Most notably, sheep and goat brucellosis caused by Bru-
cella melitensis is an intractable problem in large areas
of the Mediterranean basin and Near East, and is the
cause of significant economic livestock industry losses
and human morbidity.
B. melitensis infection in small ruminants can be con-
trolled by vaccination with a live attenuated Brucella
vaccine (Rev.1) [2,3]. Although this ‘attenuated’ vaccine
is effective when used appropriately, it remains suffi-
ciently virulent so as to cause abortion in pregnant ani-
mals and active brucellosis in man. Moreover, the
generation of anti-Brucella antibodies following vacci-
nation means that, using current serodiagnostic tests,
there are difficulties in differentiating vaccinated and
protected animals from those with true virulent infec-
tion. Non-living vaccines (mainly killed bacterin pre-
parations) have been used intermittently in the past but
have been discredited due to poor protective efficacy,
generation of inappropriate immune responses, and
poor standardizations [4]. More recently, vaccines of
this type have been revisted and are showing some suc-
cess [5]. Given the importance of Brucella zoonosis and
the current difficulties with current vaccines, the devel-
opment of an efficacious non-living defined vaccine is
imperative towards improving control of this economic-
ally significant zoonosis. DNA vaccine technology has
been successful in overcoming some of the limitations
of killed cell and subunit protein preparations and a
number of reports have shown protective DNA vaccina-
tion against brucellosis in the murine model with rela-
tively simple constructs encoding a single protective
antigen [6-11]. Indeed we previously reported protective
activity from two candidate DNA vaccines based upon
B. melitensis omp25 and ialB genes [12]. However,
naked DNA vaccination is known to be a relatively
inefficient process and protection is rarely achieved fol-
lowing a single inoculation. Several strategies have been
used to enhance the immunogenicity of various Bru-
cella DNA vaccines. For example plasmid vectors have
been used to deliver cytokines in addition to the pro-
tective antigen [13-15], and prime boost approaches
have been reported with some success. For example
Cassataro et al [16], reported moderate improvements
to protective efficacy of a DNA vaccine through use of
a heterologous prime boost strategy to deliver the
BLSOmp31 chimeric DNA vaccine. However, thus far,
none of the DNA vaccines described above have been
shown to elicit significant levels of protection in the
mouse model or target species after only a single
immunisation. Munoz-Montesino et al [17] achieved
modest protective efficacy from a single intrasplenic
inoculation of mice with a DNA vaccine based upon
Cu/Zn SOD, although equivalent quantities of this vac-
cine were not efficacious when delivered by the more
usual, intramuscular, route. Interestingly, Saez et al [18]
have recently demonstrated immunogenicity of the
Brucella Cu/Zn SOD based DNA vaccine in cattle, indi-
cating the potential of the DNA vaccine approach for
Brucella to be carried through to the target species.
Their vaccine was able to induce antigen specific T cell
proliferation and an IgG1 isotype dominated antibody
response, but protective efficacy was not investigated in
these studies. Notably, the measured quantities of IFNg,
the essential mediator of protective immunity was rela-
tively low in these studies, suggesting that modifications
may be beneficial for more efficient or efficacious vacci-
nation of livestock.
Different routes of delivery have been investigated to
improve DNA uptake and in vivo expression including
techniques such as in-vivo electroporation [19,20] and
the use of microparticulate delivery systems [21], which
have also been used with success specifically for brucel-
losis vaccination with acellular antigen extracts [5].
Encapsulation or surface adsorption of DNA to cationic
liposome preparations has also been shown to be a sim-
ple method for improving the immune response to
DNA vaccines [22,23]. Our own studies previously
demonstrated a protective effect from DNA vaccines
encoding the B. melitensis 16 M genes ialB and omp25
when delivered as four discreet intramuscular inocula-
tions given at three week intervals. Moreover, prelimin-
ary assessment of the vaccine induced immune
responses suggested specific responses were elicited
after fewer than four inoculations. Therefore, in this fol-
low up study we aimed to assess the performance of a
single dose of the candidate DNA vaccines, when deliv-
ered as either naked DNA or surface adsorbed to catio-
nic liposomes (lipoplex). Protective efficacy and vaccine
specific immune responses were measured in order to
determine if this simple method of delivery via lipoplex
could improve the efficiency of DNA vaccination, and
thereby ultimately facilitate transfer of this research to
the target animal.
Materials and methods
Experimental design and vaccine production
Plasmids encoding the Brucella proteins Omp25 and
IalB were produced as described previously [11]. The
immunogenicity and protective efficacy of the candidates
was evaluated after either, (a) the known protective regi-
men of four doses of naked DNA vaccine, (b) a single
dose of naked DNA vaccine or (c) a single dose of lipo-
plexed DNA vaccine.
Commander et al. Genetic Vaccines and Therapy 2010, 8:5
http://www.gvt-journal.com/content/8/1/5
Page 2 of 12
Plasmid based vaccines
DNA vaccines p-omp25 and p-ialB were produced as
described previously [11]. Briefly, the ialB and omp25
genes were amplified by PCR and modified to encode a
5’ Kozac signal sequence to facilitate eukaryotic expres-
sion. PCR products were cloned into the pCR3.1 vector
(Invitrogen) and the pTargeT (Promega) expression vec-
tor (omp25 product only). Sequence fidelity and orienta-
tion was checked through sequencing and restriction
enzyme fragmentation and in vitro expression from the
plasmids was verified following transfection of Cos7
cells as previously described. Bulk stocks of endotoxin
free DNA vaccine plasmids and vector control plasmid
(pcDNA3.1) in 0.1 M PBS were produced for in-vivo
studies by Plasmid Factory GmbH, (Bielefeld, Germany).
For this study plasmids were generated using the
pCR3.1 (Invitrogen) or pTargeT (Promega) backbones.
Preliminary investigations suggested that the kinetics
and quantity of in-vitro expression for the Omp25 pro-
tein was uninfluenced by the plasmid backbone (data
not shown). Thus, for the investigations described
herein, a preparation consisting of a 1:1 mixture of both
plasmid types was used as the p-omp25 vaccine. p-ialB
preparations were based upon the pCR3.1 backbone
only.
Lipoplex production
Lipid vesicles were prepared from 1-monopalmitoyl gly-
cerol, cholersterol, stearyl amine and cetyl trimethyl
ammonium bromide (CTAB (All from Sigma UK, Poole,
Dorset)) in the molar ratio 5:4:1:1, by the methods
described previously [24]. The p-ialB, p-omp25 and
pcDNA3.1 plasmids were surface adsorbed to the catio-
nic vesicles immediately prior to vaccination. Briefly, 2
ml of plasmid DNA at 1 mg/ml was added dropwise to
an equal volume of liposome preparation. The plasmid:
liposome mixture was gently mixed using a Denley
Rotary Cell Mixer for 30 minutes at 25°C, and then cen-
trifuged at 2000 rcf to sediment the complexes. 2 ml of
supernatant (SN) was removed and set aside for retro-
spective analysis of DNA content by spectrophotometry
(A260 determination) and agarose gel electrophoresis.
This data was used to determine whether adsorption of
DNA to liposomes had been successful: absence of
detectable DNA in the SN indicating that DNA was
complexed to the liposomes. Successfully adsorbed lipo-
some DNA complexes were resuspended in the remain-
ing SN by gently mixing, and used for vaccination
within one hour of production. Control solutions of non
DNA complexed liposomes were treated identically with
0.1 M PBS.
Vaccination and challenge experiments
Groups of mice (4 < n < 10) were intramuscularly
inoculated with either naked DNA (p-ialB, p-omp25 or
plasmid control pcDNA3.1) at 100 μg/mouse/dose, or
an equivalent quantity of the DNA surface adsorbed
to cationic liposomes (L-p-ialB, L-p-omp25 and
L-pcDNA3.1 respectively). Uncomplexed liposomes
(without adsorbed DNA) and PBS were administered in
equivalent dosing volumes to control groups. In each
study protective efficacy of the candidate vaccines was
compared to that of the live attenuated strain B. meli-
tensis Rev.1. Rev. 1 was administered subcutaneously as
a single dose of approximately 2 × 105 CFU per mouse
to the control groups. For assessment of protective effi-
cacy mice were challenged with approximately 1 × 104
CFU B. melitensis strain 16 M given via intraperitoneal
inoculation at 30 days post-vaccination. B. melitensis 16
M and Rev.1 strains were obtained from the VLA cul-
ture collection and propagated and prepared for use as
described previously [11]. The number of bacteria pre-
sent in the spleens of the mice at 15 ± 1 days post chal-
lenge was used to compare the protective effects of the
candidates and controls. Splenic homogenates were seri-
ally diluted and cultured on TSA (+5. I.U Penicillin)
media at 38°C, with 10% CO2 for 5 - 7 days. Bacterial
load per group was compared using one-way ANOVA
of log transformed data.
Immunological response assessments
ELISA for measurement of serological responses to
vaccination
Antibody responses were measured in colorimetric
ELISA against B. melitensis 16 M whole cell antigen
using protocols and reagents described previously [11].
The sera was also assessed against recombinant
Omp25-GST, GST and IalB proteins, in an identical
ELISA format. Purification of recombinant IalB and
Omp25 was performed by Lionex GmbH (Germany),
and these antigens were coated on Nunc Polysorb plates
at concentrations of 10 μg/ml, 10 μg/ml and 15 μg/ml
respectively. The response of individual mice at each
time point was assessed. For the measurement of
Omp25 specific responses the OD of the GST reaction
was subtracted from that of the corresponding Omp25-
GST reaction, to eliminate responses specific to the
GST tag on the recombinant protein. Positive responses
were recorded from sera reading a greater OD than the
assay Cut Off (CO). CO was determined as Mean + 3 X
standard deviation (SD) of plate specific negative con-
trol samples (Normal mouse sera at 1/40 dilution) in
ELISA.
Following assessment of individual mouse responses,
pooled samples were created for each group. The speci-
fic IgG1 and IgG2a titres were obtained from the pooled
serum samples from each group. Endpoint titres for
each group at each time point were determined as the
dilution at which the sample OD first becomes lower
than the plate Cut-off (CO) value.
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Measurement of antigen specific IFNg production
IFNg production was measured by ELISPOT following
specific antigen stimulation of splenocytes from vacci-
nated mice. Specific stimulatory antigens included Bru-
cellergene™ (Synbiotics Europe, Merial, France), a
commercially available preparation of cytosolic antigens
derived from rough strain B. melitensis B115. Bruceller-
gene™ was dialysed against PBS prior to use to remove
the preservatives, and prepared to a 40 μg/ml final con-
centration in stimulation assays. Specific recombinant
IalB [used at 15 μg/ml final concentration], recombinant
GST [10 μg/ml] or recombinant Omp25-GST [10 μg/ml]
were also used as stimulating antigens depending upon
the particular investigation. Concanavalin A at 5 μg/ml
final concentration was used as a mitogen control in
these assays, and antigen free media (DMEM complete)
was used as a no stimulation control.
Assays were conducted at three weeks post-vaccina-
tion and two weeks post-challenge in order to compare
the antigen specific immune response of candidates and
controls.
For each ELISPOT investigation (conducted three
weeks after completion of the selected vaccination proto-
col), splenocyte preparations from five animals per group
were pooled and processed to produce CD4+ depleted
cell populations and CD8+ depleted cell populations.
Anti-mouse CD4+ (L3T4) and anti-mouse CD8+ (Ly-2)
magnetic beads (Miltenyi Biotech) were used to bind the
CD4+ and CD8+ expressing cells in the total splenocyte
population and depletions were carried out using Midi-
Macs (Miltenyi Biotech) cell separation technology.
Briefly, the total splenocyte concentration was adjusted
to 1 × 109 cells per ml in ice cold FacsFlow (FF) buffer
(BD Biosciences), and three separate replicates of the cell
sample were created. One replicate was treated with anti-
CD4+ beads and another with anti-CD8+ beads (100 μl
of beads was used per ml of cell suspension). The third
replicate served as a ‘no bead’ control. Samples were
incubated on ice for 30 minutes with occasional gentle
mixing. Midi-Macs™ LS columns (Miltenyi-Biotech) were
equilibrated with ice cold FF and positioned in the mag-
netic clamps. The cell preparations were applied to the
LS columns and the fall through fraction collected in
clean sterile tubes over ice. The columns were washed
through with three volumes of ice cold FF and the total
eluate collected and washed by centrifugation in ice cold
FF. The final preparations, “CD4+ depleted”, “CD8+
depleted” or “Total/undepleted” were resuspended in a
minimal volume of ice cold FF for enumeration and then
supplemented with DMEM complete to a final concen-
tration of 5 × 106 cells per ml for use in ELISPOT.
ELISPOT nitrocellulose membrane plates (Millipore)
were prepared by coating with anti-IFNg mAb (AN18)
(MabTech, Sweden) at 15 μg/ml, overnight incubation
at 4°C in coating buffer pH 9.6. Plates were washed
twice in PBS and blocked for one hour with DMEM
complete media at 37°C prior to incubation with cells
and antigens at the concentrations described previously.
Stimulated cultures were incubated (37°C, 5% CO2) for
24 ± 2 hours, loosely wrapped in aluminium foil. Fol-
lowing incubation cells were aspirated from the filter
plates and the membrane washed four times with PBS-T
wash buffer. Anti-mouse IFNg biotinylated antibody
(MabTech, Sweden) at 1 μg/ml in PBS-B (PBS + 1%
BSA) was added and incubated at 25°C. Plates were
washed four times with PBS-T prior to the addition of
Streptavidin-alkaline phosphatase reagent (GE Bios-
ciences) (1 in 1000 in PBS-B) and incubation at 25°C for
one hour. Plates were then washed four times with PBS-
T and then twice with distilled water, before application
of 0.2 μM filtered BCIP/NBT (BCIP/NBT Fast Tabs,
Sigma UK) solution for developing the spots. The reac-
tion was halted by rinsing in distilled water as soon as
the colour development in the ConA control stimulation
wells was complete - with wells showing a confluent
block of colour. Plates were then fumigated to ensure
sterility and air dried before reading using an AID ELI-
SPOT reader.
All animal work was approved by the VLA Ethics
Committee, and in line with A(SP)A 1986 regulations.
Results
Immunological responses to vaccination and challenge
Serological response to vaccination
The serological response of the mice to vaccination was
investigated by ELISA. Antigen specific IgG1 and IgG2a
were measured from sera collected at three weeks post-
vaccination. These data are presented in table 1.
Data from all naked DNA vaccinated groups indicated
development of a Th1 biased serological response. The
four dose p-omp25 vaccine regimen resulted in detect-
able Omp25 specific IgG1 and IgG2a from 100% of
mice, with titres of 1/640 and 1/1250 respectively. The
single dose group generated a more modest antibody
response with 60% of the mice noted to have Omp25
specific IgG2a antibodies. The titre of the sera pooled
from this group was 1/320. Omp25 specific IgG1 antibo-
dies were not detected from any mice in this group.
A single dose of the lipoplex p-omp25 resulted in an
overall stronger humoral immune response than the sin-
gle dose naked DNA with 100% and 70% of vaccinates
shown to have Omp25 specific IgG2a and IgG1 respec-
tively. The titres for the pooled sera from this vaccine
group were 1/320 and 1/1000, for IgG1 and IgG2a
respectively. Thus, the delivery of the vaccine as a lipo-
plex appeared to enhance antibody production, and pro-
mote a more balanced IgG1/IgG2a antibody profile than
naked DNA.
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For the ialB based vaccines, the four dose regimen
resulted in strong antibody responses with 100% of mice
producing specific IgG1 and IgG2a. Group pooled sera
titres were > 1/5000 for both isotypes. Unfortunately no
antibody response was apparent after a single inocula-
tion with naked DNA. However, a single dose lipoplex
vaccination with this construct produced measurable
IalB specific responses in 80% of mice (IgG1 response),
albeit of a relatively low titre (1/270). One of the ani-
mals in the group (10%) was demonstrated to be posi-
tive in the IgG2a specific tests (OD > 0.25). However, in
the pooled group titration this response was diluted
such that the overall group response would be consid-
ered negative at 1/40.
Overall the data suggests that delivery of a single dose
of DNA as a lipoplex resulted in an improvement in
antibody production for both candidates, in comparison
to that elicited by naked DNA. For example the lipoplex
p-omp25 vaccine was able to induce an equivalent anti-
body response to that observed from the four dose regi-
men. More strikingly, a single inoculation of lipoplexed
p-ialB elicited detectable antibody from mice whereas
single dose naked DNA did not. However, the single
dose lipoplex p-ialB vaccination was unable to elicit an
equivalent antibody response to that achieved following
four doses of naked DNA.
Cellular immune responses to vaccination and infection
Antigen specific IFNg production was measured follow-
ing in vitro stimulation with Brucella specific antigens
(Brucellergene™, recombinant IalB, recombinant
Omp25), and further information on the cellular origins
of the IFNg responses were derived from specifically iso-
lated CD4+ and CD8+ depleted splenocyte populations.
Figure 1 summarises the antigen specific IFNg
responses (total ΔSFC/106 cells) elicited by each of the
different vaccination strategies. Table 2 summarises the
data obtained from ELISPOT assays to measure IFNg
production from CD4+ or CD8+ depleted splenocyte
populations from vaccinated mice. The data reveals that
each vaccine regimen is capable of inducing antigen spe-
cific IFNg production from in vitro restimulated spleno-
cytes. However, there are notable differences, both
quantitative and qualitative, between the responses eli-
cited by the different regimens and vaccines.
A comparison of Rev.1 based immunity and that gen-
erated by the two candidate vaccines is not entirely
appropriate due to the differences in live versus subunit
vaccination approaches, but can be used to benchmark
the type of response required for effective protective
efficacy. Rev.1 immunised animals produce Brucella spe-
cific IgG1 and IgG2a and a CD4+ T cell dominated
IFNg response. Responses from the Rev.1 vaccinated
animals revealed antibody and IFNg production in
response to specific antigens Brucellergene™ and Omp25
but not to IalB, suggesting that this antigen does not
have a major role to play in immunity generated by this
vaccine.
Significant differences in IFNg production were
observed between the different vaccination strategies in
the mice receiving the omp25 based DNA vaccines. The
four dose naked DNA regimen (p-omp25 [X4]) was
found to result in the strongest IFNg response to
Table 1 Humoral immune responses to vaccination
Titre (and percentage of animals responding) of specific IgG1 and IgG2a antibodies in ELISA.
ELISA Omp25-GST IalB 16M
IgG1 IgG2a IgG1 IgG2a IgG1 IgG2a
p-omp25 [X1] Neg 1/320 (60%) ND ND Neg Neg
p-omp25 [X4] 1/640 (100%) 1/1280 (100%) ND ND 1/420 (100%) 1/520
(100%)
L-p-omp25 1/320 (70%) 1/1000 (100%) ND ND 1/640 (70%) 1/1280 (100%)
p-ialB [X1] ND ND Neg Neg Neg Neg
p-ialB [X4] ND ND 1/5210 (100%) 1/5210 (100%) 1/5120
(100%)
1/5120
(100%)
L-p-ialB ND ND 1/270 (80%) 1/40*(10%) 1/500 (80%) 1/120 (10%)
pcDNA3.1 [X1] Neg Neg Neg Neg Neg Neg
pcDNA3.1 [X4] Neg Neg Neg Neg Neg Neg
L-pcDNA3.1 Neg Neg Neg Neg Neg Neg
Uncomplexed Liposome Neg Neg Neg Neg Neg Neg
Rev.1a Neg Neg Neg Neg Neg Neg
Rev.1b 1/640 (100%) 1/640 (100%) Neg Neg 1/2560 (100%) 1/2560 (100%)
PBS Neg Neg Neg Neg Neg Neg
Rev.1a, serum sample taken at two weeks post-vaccination. Rev.1b serum sample taken at 12 weeks post-vaccination. Neg: All individual OD values below assay
C/O. ND: Sample not tested. The number of individual sera per group for each assay n ≥ 10.
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Omp25 antigen The single dose of naked DNA also
resulted in measurable IFNg production which was not
considered significantly different to that achieved by the
four dose regimen. Notably, a single dose of lipoplex
omp25 resulted in a lower total IFNg response than the
naked DNA approaches. Statistical analysis (Mann-
Whitney test) did not reveal a significant difference in
the quantity of IFNg producing cells elicited between
the single dose naked DNA and single dose lipoplex for-
mulations (p > 0.05) or between the single dose naked
DNA and multi-dose naked DNA regimen (p > 0.05),
but did suggest a significant difference between the total
IFNg cells for multi-dose and single lipoplexed DNA
regimens (p < 0.05). Overall, these data show that each
omp25 based vaccine elicits detectable levels of IFNg
secreting cells and suggests that delivery of as a lipoplex
does not notably augment the cellular response com-
pared to that achieved by naked DNA vaccination.
CD4+ and CD8+ subset analysis for the omp25 based
vaccines suggested that the CD8+ subset of the spleno-
cyte population were responsible for the majority of
observed IFNg production in both the single or multi-
dose naked DNA vaccinated groups. Whilst depletion of
CD8+ cells from total splenocytes did not abrogate the
detectable response there was a considerable decrease in
the detectable SFC (85%), indicating the majority of
IFNg producing cells to be a CD8+ phenotype. However,
when this vaccine was delivered as a lipoplex the cellular
contributions appear to be altered with the depletion of
CD4+ cells having the most dramatic effect upon detect-
able SFC, suggesting that whilst cellular responses are
not quantitatively improved by lipoplex delivery there
may be an effect on the priming of different subsets.
The multiple dose p-ialB naked DNA regimen
resulted in a similar total of detectable antigen specific
SFC to that observed for the equivalent delivery strategy
with p-omp25. Relatively few antigen specific SFC were
observed when a single dose p-ialB naked DNA vaccine
was used, but lipoplex delivery of this vaccine prompted
a modest increase in the number of SFC. The difference
Figure 1 Total ΔSFC per million cells detected in response to
stimulation with (a) Omp25 antigen or (b) IalB antigen, for
each of the vaccine groups. Measured from splenocytes
harvested at three weeks post-vaccination. (a) stimulation of
splenocytes with Omp25 antigen (10 ug/ml). (b) Stimulation of
splenocytes with IalB antigen (15 ug/ml). Bars represent the total
ΔSFC detected per million splenocytes for each vaccine (Number of
spots detected in stimulated sample - number detected in
corresponding unstimulated sample). Error bars represent the
standard deviation of replicate samples.
Table 2 IFNg ELISPOT data for the ialB and omp25 based vaccines showing the contribution of CD4+ and CD8+ T cells
to the total response
Vaccine Net responsive cells
Total cell population CD4+ depleted cell population CD8+ depleted cell population
Stimulation with Omp25 (10 μg/ml)
p-omp25 [X1] 50.8 ± 24.9 27.8 ± 2.3 [↓45%] 11.3 ± 2.3 [↓78%]
p-omp25 [X4] 73.3 ± 20.3 41.0 ± 5.2 [↓44%] 10.8 ± 3.5 [↓85%]
L-p-omp25 25.0 ± 0.77 2.8 ± 0.08 [↓89%] 13.0 ± 0.9 [↓48%]
Stimulation with IalB [15 μg/ml]
p-ialB [X1] 12.75 ± 1.75 0 0
p-ialB [X4] 75.02 ± 18.37 11.0 ± 4.85 [↓85%] 36.25 ± 2.92 [↓52%]
L-p-ialB 23.25 ± 6.06 0 0
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between single and multi-dose vaccine elicited SFC was
considered significant (p < 0.05, Mann-Whitney test),
suggesting multiple vaccinations are required for effec-
tive T cell priming. The difference in T cell response
between single dose naked DNA and lipoplexed p-ialB
was not found to be significant in these analyses. Never-
theless, the modest increase in SFC suggests that liposo-
mal delivery of p-ialB has the potential to enhance the
capacity of this vaccine for inducing an antigen specific
cellular immune response.
For the four dose naked p-ialB protocol the depletion
of CD4+ cells resulted in the most notable reduction of
SFC (85%), suggesting that these cells were the principal
producers of the IFNg. This contrasts with the result
from the p-omp25 vaccines where the CD8+ subset are
dominant for IFNg production. Unfortunately, in the
single dose studies the depletion of either subset (CD4+
or CD8+) abrogated the detectable IFNg response, and
hence it is not possible to deduce whether one subset
has a more prominent role to play in IFNg production.
ELISPOT analysis of total splenocytes was also per-
formed post-challenge, to determine whether the differ-
ent vaccines or vaccination strategies resulted in different
immune profiles during progression or clearance of infec-
tion. The data revealed the presence of IFNg secreting
cells following stimulation with Omp25 in all groups of
animals. Relatively high numbers of SFC (> 25 SFC) were
determined in all groups and in many cases automated
plate reading revealed saturated responses. Saturation
was estimated to be equivalent to ≥ 200 SFC. A relation-
ship between the number of Omp25 specific SFC
detected post-challenge and previous exposure to this
antigen (through vaccination with the omp25 based pre-
parations or Rev.1) was not demonstrable. In contrast,
the post-challenge IalB stimulation data showed that only
groups of animals that had been deliberately exposed to
this antigen had significant IalB specific responses post-
challenge. Significant production of IFNg was apparent
from the mice vaccinated with multi-dose (> 200 SFC) or
single dose naked DNA (6.0 ± 0.62 SFC) or single dose
lipoplex DNA (43.5 ± 3.2 SFC) but not from any of the
non-immune control groups. These findings suggest that
ialB vaccines have primed the immune response to this
antigen which may be weakly expressed during the early
stages of infection, but may be an important protective
antigen.
Demonstration of protective efficacy of the different
vaccine regimens
Protective efficacy was measured in three experiments.
Each individual study contained appropriate positive
(Rev.1 immunised) and negative (PBS inoculated) con-
trol groups. The mice received 2.05 × 105 CFU per
mouse (study 1), 2.26 × 105 CFU per mouse (study 2)
and 1.95 × 105 CFU per mouse (Study 3) of Rev.1 vac-
cine control. At challenge mice received 2.16 × 104 CFU
per mouse (study 1), 2.66 × 104 CFU per mouse (study
2), and 2.26 × 104 CFU per mouse (study 3), of B. meli-
tensis 16 M. Upon completion of all three experiments
each individual study and the combined data was ana-
lysed to enable comparison of each of the various vac-
cine candidates and protocols. Direct comparison of the
recovered bacterial load from the Rev.1 and (PBS) naïve
controls of each experiment revealed no significant dif-
ference between studies (Two-way ANOVA and Dun-
nets post-test, p > 0.05) suggesting that the studies were
consistent enough to permit qualitative inter-study com-
parison of efficacy of test candidates.
Table 3 shows the mean Log10 CFU per spleen
B. melitensis 16 M recovered from spleens of mice at
15 ± 1 day post-challenge. In all three studies the Rev.1
vaccine provided expected levels of protective effect,
ranging between 2.04 and 3.75 PU across the studies.
Similarly, the four dose vaccination regime for p-ialB or
p-omp25 resulted in the expected statistically significant
reduction in bacterial load in comparison with the naïve
mice. The PU for the four dose naked DNA vaccination
regimens ranged from 2.15 to 3.45 in these studies, indi-
cating equivalent protective efficacy to Rev.1 in this
model and confirming the findings of previous studies.
A single dose of either the p-ialB or p-omp25 naked
DNA vaccines resulted in a very slight reduction in bac-
terial load compared with the concurrent naïve control
groups (0.80 and 0.55 PU respectively) but analysis did
not reveal this reduction to be statistically significant.
Furthermore, a similar value of 0.43 PU was obtained
for the empty vector control in these studies, thereby
indicating that a single dose of either p-ialB or p-omp25
delivered as naked DNA was unable to provide a signifi-
cant antigen specific protective effect.
The single dose lipoplexed vaccines resulted in a slight
reduction in bacterial load in comparison to the naïve
controls. In these studies the difference between vacci-
nated animals and naïve (PBS) animals amounted to 1.0
PU for L-p-ialB and 0.81 for L-p-omp25. In both cases
the PU measured for the lipoplex version of the single
dose vaccine exceeded that of the equivalent dose of
naked DNA, suggesting a possible improvement in vac-
cine performance through delivery as a lipoplex. How-
ever, these differences were not determined to be
statistically significant (ANOVA with Dunnets post-hoc
test, p > 0.05). Furthermore, the comparison of bacterial
loads for the naïve controls and the lipoplex samples
did not reveal a statistically significant protective effect
from lipoplexed vaccines.
Overall, the protective efficacy investigations con-
firmed the findings that p-ialB and p-omp25 vaccines
provide significant protective efficacy when delivered in
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a regimen of four discrete 100 μg inoculations given at 3
week intervals. Unfortunately, a single dose of these vac-
cines was unable to provide a robust or significant pro-
tective effect when delivered either as naked DNA or
lipoplex. Notably, lipoplex delivery does appear to
increase the protective efficacy of a single dose each vac-
cine but not to a statistically significant level.
Discussion
Previous studies [11] indicated a protective effect from
two candidate DNA vaccines based upon the omp25
and ialB genes of B. melitensis in the murine model of
brucellosis. Protective efficacy was achieved after four
separate 100 μg inoculations. This finding was con-
firmed in the present study. However, in order for these
vaccines to be practical for use in livestock the number
of inoculations and quantity of DNA required to elicit a
protective response ideally needs to be reduced. The
relatively poor immunogenicity of naked DNA vaccines
is well established and considerable effort has been
invested in assessment of vaccination protocols, formu-
lations and strategies to improve their potency (for
review see [25,21]. Lipoplex delivery of DNA is one
such strategy which probably works through a combina-
tion of a potent adjuvant effect [26,27] and the presence
of the lipid providing the plasmids with some protection
against degradation by nucleases in vivo. Lipoplexing as
a delivery strategy therefore has potential to improve
antigen delivery to antigen presenting cells (APCs). To
this end we chose to re-evaluate our two candidate
DNA vaccines as single doses of naked DNA (100 μg
per mouse) and an equivalent quantity of the DNA
surface adsorbed to a novel formulation of cationic lipo-
somes (lipoplex).
We found that each of our single dose vaccines was
able to induce significant and appropriate antigen speci-
fic immune responses, albeit to a lesser extent than the
multiple dose naked DNA strategy. Furthermore, the
use of lipoplex delivery resulted in marked changes to
detectable specific immune responses suggesting
improvements in antibody generation or CD4+ T cell
priming. Each of the single dose formulations showed a
modest (but not statistically significant) control of bac-
terial load in challenged mice. Whilst the lack of a
robust protective effect is disappointing it is unsurpris-
ing as with the exception of a Cu/Zn SOD plasmid
delivered directly to the spleen[17], demonstrable pro-
tective efficacy against brucellosis has yet to be demon-
strated from a single inoculation with a DNA vaccine.
The lipoplex strategy appears to have been successful
in boosting the humoral immune responses elicited by
both candidate vaccines. In the case of the omp25
Table 3 The protective effect of vaccination with naked DNA or liposome formulated DNA
Vaccine group Brucella CFU per spleen Brucella per spleen as a % of challenge dose Protection units
Experiment 1: A comparison of single dose naked DNA vaccine efficacy
Rev.1 2.95 ± 0.35* 67.8 2.04*
PBS 5.00 ± 0.05 114.8 0
pcDNA3.1 [X1] 4.56 ± 0.31 104.8 0.43
p-omp25 [X1] 4.45 ± 0.44 102.3 0.55
p-ialB [X1] 4.19 ± 0.42 96.4 0.80
Experiment 2: p-omp25 [X4] compared with L-p-omp25 [X1]
Rev.1 1.47 ± 0.82* 33.2 3.35*
PBS 4.83 ± 0.29 109.2 0
pcDNA3.1 [X4] 4.80 ± 0.21 108.5 0.02
p-omp25 [X4] 1.40 ± 0.69* 31.7 3.42*
L-p-omp25 [X1] 4.01 ± 0.14* 90.8 0.81*
L-pcDNA3.1 4.86 ± 0.44 109.8 -0.03
Experiment 3: p-ialB [X4] compared with L-p-ialB
Rev.1 1.94 ± 0.77* 44.8 2.12*
PBS [X4] 4.10 ± 0.68 93.6 0
PcDNA3.1 [X4] 3.75 ± 0.36 86.1 0.32
p-ialB [X4] 1.91 ± 0.93* 44.0 2.15*
L-p-ialB [X1] 3.07 ± 1.08 70.5 1.00
L-pcDNA3.1 3.37 ± 0.58 77.5 0.70
Brucella CFU per spleen: Log Brucella CFU per spleen ± standard deviation.
Protection units = Log Brucella CFU per spleen of unvaccinated mice - Log Brucella CFU per spleen of vaccinated mice. % Challenge dose: (Log CFU Brucella per
spleen/Log CFU challenge dose) × 100.
* indicates statistically significant reduction of Brucella CFU per spleen compared to PBS controls in the same study (One Way ANOVA analysis with Dunnets
post-hoc test, p < 0.05).
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vaccines this was seen as an increase in specific IgG titre
and the number of responsive animals observed in the
single dose lipoplexed p-omp25 group compared to the
single dose naked DNA group. For the p-ialB vaccine
specific antibodies were not detected from a single dose
with naked DNA but lipoplex delivery resulted in mea-
surable specific IgG1 from 80% of the mice. Thus,
demonstrating that lipoplex delivery was able to increase
the immunogenicity of the candidate vaccines and deli-
ver a stronger or detectable response after a single
immunisation. Similar improvements to antibody gen-
eration through use of liposomes to deliver DNA vac-
cines have been reported by Perrie [28] and more
recently by Hiszczyńska-Sawicka [29]. The relevance of
antibodies for clearance of Brucella remains undeter-
mined at this point. Defining the role of the specific
antibodies in the protective effect was outside the remit
of this study, and more generally although antibodies
are a significant component of the immune response to
natural infection they are not considered to be
protective.
IFNg is understood to be the key effector in control
of brucellosis in both the murine model [30] and target
species [31]. Our findings indicate that antigen specific
IFNg was produced by both CD4+ and CD8+ T cells
in response to IalB and Omp25 antigens. The protec-
tive multi-dose regimens elicited similar total numbers
of antigen specific IFNg effector cells (around 75 ΔSFC
per million) for both candidates. For the ialB based
vaccines both the single dose strategies produced rela-
tively low quantities of IFNg secreting T cells com-
pared with the protective boosting strategy. Therefore
the relationship between boosting and protection
appears to be simple with a threshold of priming
reached during the multiple administrations that was
not achieved by a single dose. Whether this is due to
increased input of antigen or temporal development of
the response was not determined in this study. Nota-
bly, the lipoplex delivery did result in a modest
increase in the number of antigen specific IFNg secret-
ing cells in comparison with the single dose naked
DNA. The demonstration of post-challenge IalB speci-
fic responses further supports the notion that the vac-
cine primes cellular responses. Overall the IalB data
suggested that a single dose of naked DNA is capable
of priming T cell responses and lipoplexing can
improve upon the priming effect.
Interestingly, for the p-omp25 candidate lipoplex
delivery does not appear to result in a direct improve-
ment of T cell priming. The number of antigen specific
T cells elicited by p-omp25 was not significantly differ-
ent (p > 0.05) between single and multi-dose naked
DNA or between lipoplex and naked DNA single dose
administrations, suggesting that neither boosting nor
lipoplexing were able to quantitatively improve T cell
priming for this candidate.
In addition to looking for quantitative differences in T
cell priming capacity between the various vaccines we
also sought to characterise the basic phenotypes of cells
involved in the immune response. Both CD4+ and CD8
+ T cells have been shown to contribute to the control
of Brucella growth in the BALB/c mouse in adoptive
transfer studies [32] and both are implicated in the con-
trol of Brucella infection in ruminant species [31]. Addi-
tional studies involving in vivo depletion strategies have
indicated that the involvement of CD8+ cells is crucial
in mice [33-35], and that passive transfer of IFNg secret-
ing CD4+ cells from mice immunised with live vaccines
can protect naïve mice against challenge [35,36]. Avail-
able data therefore suggests that both cell types have a
role to play in control of brucellosis, and therefore the
basic phenotypic composition of the vaccine induced
immune response was measured in this study to deter-
mine whether particular cell subsets were responsible
for the protective effect. Although the total number of
responder cells was similar for both protective vaccina-
tion strategies, the balance of CD4+/CD8+ responding
cells was different with the p-ialB group response domi-
nated by CD4+ T cells and the p-omp25 group response
dominated by CD8+ T cells.
Interestingly, the lipoplex delivery of p-omp25 altered
the profile of responsive T cells from a mainly CD8+ T
cell response to a CD4+ dominated response, suggesting
a possible effect of lipoplex delivery was to favour or
augment CD4+ T cell priming. Indeed, increased CD4+
mediated production of IFNg has previously been
reported as a consequence of using liposome-DNA com-
plexes as an adjuvant for genital herpes vaccines [37]
and for delivery of a mycobacterial hsp65 DNA vaccine
[38]. Unfortunately, the relative merits of improved CD4
+ priming (or decreased CD8+ priming) by the lipoplex
approach cannot be determined in this study, since
neither the CD8+ dominated naked DNA singly dosed
animals nor the CD4+ dominated lipoplex singly dosed
animals were able to promote protection. Similarly, the
relative contribution of CD4+ and CD8+ T cells for the
single dose p-ialB vaccines could not be measured in
these studies, and therefore whether CD4+ or CD8+
responses are more important for the development of a
protective response to this candidate cannot be deduced
from this study. Overall, our assessment of T cell
responses suggests that the administration of lipoplexed
DNA appears to favour CD4+ priming and antibody
generation, and therefore additional strategies to
improve CD8+ priming may be required.
A direct comparison of our two candidates suggests
that Omp25 is a more immunogenic antigen than IalB.
Omp25 is an immunogenic protein which is recognised
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by the sera of infected and convalescent animals. Our
own studies [12] suggested that approximately 96% of
B. melitensis infected goats produce specific antibody
against this protein. It shares considerable homology
with the Omp31 antigen and our results indicate that
our p-omp25 vaccine elicits a similar response to that
observed to the pCI-omp31 plasmid vaccine [9]. Notably
the role of IalB in Brucella virulence and pathogenicity
remains undefined. This antigen was shown to be
expressed [39] by both virulent B. melitensis 16 M and
the vaccine strain Rev.1, and it bears significant homol-
ogy to the IalB gene of B. bacilliformis which is involved
in the process of invasion of erythrocytes for this patho-
gen [40]. The protein is immunogenic: specific antibody
against this protein is detectable in sera from infected
sheep and goats (~76%) [12], but its role in Brucella
pathogenesis remains undefined at this stage.
Both forms of single dose p-omp25 give rise to a high
number of IFNg secreting cells and both IgG1 and IG2a
antibodies, whereas p-ialB does not give as notable a
response after a single inoculation unless lipoplexed.
Antigen specific differences such as the presence or
absence of secretory signals will influence the in vivo
expression and consequent presentation to the immune
system. For example the presence of a secretory signal
in the ialB gene is likely to result in better presentation
to CD4+ T cells, although this has not been fully inves-
tigated in these studies. Furthermore the plasmid struc-
ture may influence antigen presentation. Notably, the
ialB based vaccine is based solely on one type of plas-
mid backbone, whereas the omp25 vaccine is a mixture
of two plasmid constructs. Studies with the pTargeT
backbone were initially undertaken because this plasmid
is designed to have improved expression capacity. How-
ever, previous in vitro expression studies with the two
separate constructs did not reveal any difference in the
ability of either construct to express the Omp25 protein.
Moreover, in the current study the protective efficacy
and total T cell response of mice receiving either candi-
date vaccine in a multi-dose strategy were similar
despite the presence of the pTargeT backbone in one
candidate vaccine and not the other. However, the dif-
ferences in the T cell subsets contributing to this pro-
tective response (p-ialB vaccinated animals elicited
mainly CD4+ antigen specific T cells and p-omp25 vac-
cinated animals produced mainly CD8+ antigen specific
T cells) may be related to the presence or absence of
the pTargeT backbone in the formulation. Others have
shown that the plasmid backbone, through presence of
different CpG motifs and/or Intron elements can have a
significant effect on the outcome of DNA vaccination
(for review see [41]). Further study to determine the
influence of the plasmid backbone and the nature of
antigen presentation and T cell priming from both the
IalB and Omp25 candidate vaccines may be useful in
guiding further development of these vaccines and iden-
tifying appropriate delivery or adjuvanting strategies.
In the recent study by Rosada et al [38] a similar
approach to DNA vaccine delivery was assessed whereby
cationic liposomes were complexed with the DNA-
Hsp65 candidate and demonstrated to engender protec-
tion against M. tuberculosis in a mouse model. Similarly
to our findings, the liposomised DNA was effective in
promoting specific immune responses, but a single dose
of the vaccine was not protective when delivered intra-
muscularly. However, significant protective efficacy
against intratracheal challenge was observed when it was
delivered intranasally suggesting a potent role for a
more localised protective effect. This raises the possibi-
lity that alternate delivery routes for our lipoplex vac-
cines may prove beneficial for protecting against more
naturally acquired forms of brucellosis (eg: intranasal,
oral and aerosol forms of challenge), but this remains to
be demonstrated experimentally. Alternate liposome for-
mulations may also be beneficial. Singha et al [42] have
demonstrated successful improvement of immunogeni-
city and protective efficacy for a Cu/Zn SOD based
DNA vaccine through encapsulation in an E. coli lipid
based liposome termed an Escherichiosome.
Conclusions
In conclusion, our study has demonstrated an improve-
ment in humoral immunity through delivery of the plas-
mids surface adsorbed to cationic liposomes.
Lipoplexing resulted in increased antibody titres for
both ialB and omp25 vaccines compared to the equiva-
lent single dose naked DNA vaccine. The effect on the
cellular immune response was more subtle, with lipoplex
p-ialB having a noticeable immunopotentiating effect,
but lipoplexed p-omp25 contributing to a change in the
dominant phenotype of responsive cells. Overall, the
data suggest that the liposome formulation is beneficial
for promotion of CD4+ T cell responses and antibody
generation. The properties of this liposome formulation
may benefit vaccine development projects where antibo-
dies and CD4+ T cells are the principal mediators of the
protective effect. In terms of Brucella vaccine develop-
ment aims, whilst the liposome delivery effect is signifi-
cant it is unfortunately insufficient to protect against
challenge with virulent Brucella and further work is
necessary to develop these vaccines to the point where
single dose delivery strategies are effective. In particular,
since CD8+ T cells are essential in Brucella control an
assessment of cytotoxic effectors, and methods to aug-
ment CD8+ priming would be advocated for future
investigations. Simple experiments to determine the
effectiveness of the naked DNA canidates delivered in
fewer than four doses, delivery in a prime-boost
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formulation with homologous recombinant protein, or
delivery of the two vaccines in a combination formula-
tion, may also assist with determining the potency of
these vaccines and to demonstrate areas for potential
improvement. Further investigation and possible refine-
ment of the nature of adsorption of the DNA to the
liposomes are also warranted. These studies were out-
side the remit of the described investigation, but are cer-
tainly points for consideration in the future. Overall,
further analysis of the development, kinetics, longevity
and sustainability of the response to Omp25 and IalB is
required before real progress can be made toward pro-
tective efficacy from a single dose of these promising
vaccine candidates.
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